Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: A proof-of-concept trial (SAKK 23/03)

Endocrine-Related Cancer

Volumn 18, Issue 2, 2011, Pages 257-264

  Koeberle, D ^a   Ruhstaller, T ^a   Jost, L ^b   Pagani, O ^c   Zaman, K ^d   Von Moos, R ^e   Oehlschlegel, C ^a   Crowe, S ^f   Pilop, C ^f   Thuerlimann, B ^a  

^a Kantonsspital St Gallen Division of Oncology Haematology   (Switzerland)

^b University Hospital Bruderholz   (Switzerland)

^c ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e Kantonsspital Chur   (Switzerland)

^f SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LETROZOLE; TRASTUZUMAB;

ADVANCED CANCER; ANOREXIA; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER GROWTH; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; HERPES ZOSTER; HUMAN; LUNG INFECTION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; SIDE EFFECT; TOOTH INFECTION; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NITRILES; POSTMENOPAUSE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TREATMENT OUTCOME; TRIAZOLES;

EID: 79953222210     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-10-0317     Document Type: Article

References (27)

1. Ali S & Coombes RC 2002 Endocrine-responsive breast cancer and strategies for combating resistance. Nature Reviews. Cancer 2 101-112. (doi:10.1038/nrc721)
2. Arpino G, Wiechmann L, Osborne CK & Schiff R 2008 Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocrine Reviews 29 217-233. (doi:10.1210/er.2006-0045)
3. De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, Tortora G, D'Agostino D, Caputo F, Cancello G et al. 2005 A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clinical Cancer Research 11 4741-4748. (doi:10.1158/1078-0432.CCR-04-2569)
4. Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E et al. 2008 Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. Journal of Clinical Oncology 26 1059-1065. (doi:10.1200/JCO.2007.12.9437)
5. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ & Panel members 2009 Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Annals of Oncology 20 1319-1329. (doi:10.1093/annonc/mdp322)
6. Huober J, Fasching P, Paepke S, Kubista E, Barsoum M, Wallwiener D & Harbeck N 2009 Letrozole in combination with trastuzumab is superior to letrozole monotherapy as first line treatment in patients with hormone-receptor-positive, HER2-positive metastatic breast cancer (MBC) - results of the eLEcTRA trial. Cancer Research 69 (Supplement 3) Abstract 4094 737-738. (doi:10.1158/0008-5472.SABCS-09-4094)
7. Hynes NE & Lane HA 2005 ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Reviews. Cancer 5 341-354. (doi:10.1038/nrc1609)
8. Inoue K, Nakagami K, Mizutani M, Hozumi Y, Fujiwara Y, Masuda N, Tsukamoto F, Saito M, Miura S, Eguchi K et al. 2010 Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group. Breast Cancer Research and Treatment 119 127-136. (doi:10.1007/s10549-009-0498-7)
9. Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ et al. 2009 Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. Journal of Clinical Oncology 27 5538-5546. (doi:10.1200/JCO.2009.23.3734)
10. Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A et al. 2009 Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. Journal of Clinical Oncology 27 5529-5537. (doi:10.1200/JCO.2008.20.6847)
11. Marcom PK, Isaacs C, Harris L, Wong ZW, Kommarreddy A, Novielli N, Mann G, Tao Y & Ellis MJ 2007 The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Research and Treatment 102 43-49. (doi:10.1007/s10549-006-9307-8)
12. Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S & Schiff R 2006 Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive HER-2/neu-positive breast cancer. Cancer Research 66 8266-8273. (doi:10.1158/0008-5472.CAN-05-4045)
13. Mauriac L, Keshaviah A, Debled M, Mouridsen H, Forbes JF, Thürlimann B, Paridaens R, Monnier A, Láng I, Wardley A et al. 2007 BIG 1-98 Collaborative Group; International Breast Cancer Study Group. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Annals of Oncology 18 859-867. (doi:10.1093/annonc/mdm001)
14. Munzone E, Curigliano G, Rocca A, Bonizzi G, Renne G, Goldhirsch A & Nolè F 2006 Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. Breast Cancer Research 8 R4 (Erratum in: Breast Cancer Research 2006 8(5): 407). (doi:10.1186/bcr1366)
15. Normanno N, Morabito A, De Luca A, Piccirillo MC, Gallo M, Maiello MR & Perrone F 2009 Target-based therapies in breast cancer: current status and future perspectives. Endocrine-Related Cancer 16 675-702. (doi:10.1677/ERC-08- 0208)
16. Osborne CK, Shou J, Massarweh S & Schiff R 2005 Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clinical Cancer Research 11 865-870.
17. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C et al. 2005 Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New England Journal of Medicine 353 1659-1672. (doi:10.1056/NEJMoa052306)
18. Prat A & Baselga J 2008 The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nature Clinical Practice. Oncology 5 531-542. (doi:10.1038/ncponc1179)
19. Ring A & Dowsett M 2004 Mechanisms of tamoxifen resistance. Endocrine-Related Cancer 11 643-658. (doi:10.1677/erc.1.00776)
20. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA et al. 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England Journal of Medicine 353 1673-1684. (doi:10.1056/NEJMoa052122)
21. Sabnis GJ, Jelovac D, Long B & Brodie A 2005 The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Research 65 3903-3910. (doi:10.1158/0008-5472.CAN- 04-4092)
22. Sabnis G, Schayowitz A, Goloubeva O, Macedo L & Brodie A 2009 Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen. Cancer Research 69 1416-1428. (doi:10.1158/0008-5472.CAN-08-0857)
23. Sabnis G, Goloubeva O, Gilani R, Macedo L & Brodie A 2010 Sensitivity to the aromatase inhibitor letrozole is prolonged after a "break" in treatment. Molecular Cancer Therapeutics 9 46-56. (doi:10.1158/1535-7163.MCT-09- 0696)
24. Schiff R, Massarwah S, Shou J & Osborn CK 2003 Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor co regulators modulate response. Clinical Cancer Research 9 (Supplement) 447-454.
25. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A & McGuire WL 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 177-182. (doi:10.1126/science.3798106)
26. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute 92 205-216. (doi:10.1093/jnci/92.3.205)
27. Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, Paulazzo G, Lyass L, Trusk P, Hill J et al. 2006 A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. PNAS 103 7795-8000. (doi:10.1073/pnas.0602468103)